Speaker Profile

M.D., Ph.D., President & CEO, Gritstone Bio Inc.

Andrew Allen, M.D., Ph.D. co-founded Gritstone bio, Inc. in 2015 and is a board member. In 2009, Dr. Allen co-founded Clovis Oncology and served as chief medical officer until 2015, driving development of rucaparib, a PARP inhibitor. Prior he was chief medical officer at Pharmion Corporation, developing Vidaza, the first DNA methylation inhibitor, until acquisition by Celgene in 2008. Dr. Allen also served in clinical development leadership roles at Chiron Corporation and Abbott Laboratories, and worked at McKinsey & Company. He currently serves on the board of directors of TCR2 Therapeutics and Sierra Oncology (both public) and Revitope Oncology and Verge Genomics (both private). He previously served on the board of Epizyme (first approved histone methylation transferase inhibitor) and Cell Design Labs (acquired by Gilead Sciences in 2017). Dr. Allen qualified in medicine at Oxford University and received a Ph.D. in immunology from Imperial College in London.

Self-Amplifying mRNA Multi-antigen Coronavirus Vaccine
First generation COVID-19 vaccines deliver Spike to induce protective neutralizing antibodies. Spike mutations can attenuate such narrow immunity. Gritstone bio has developed a self-amplifying mRNA vaccine platform that delivers Spike plus additional conserved T cell epitopes from other viral genes. Strong immunity has been demonstrated in NHP. Human data are being generated.

 Session Abstract – PMWC 2022 Silicon Valley

The COVID-19 pandemic is driving the unprecedented transformation of the global medical research ecosystem through the search for effective new therapeutics that can help ease symptoms and prevent death among COVID-19 patients.

  • SARS_CoV-2 Outbreak Surveillance (PANEL)
    Session Chair: Charles Chiu, UCSF
    - Bronwyn MacInnis, The Broad Institute - Duncan MacCannell, CDC
    - Christopher E. Mason, Weill Cornell Medicine
    - Joel Sevinsky, Theiagen
  • Experiences from the Front Lines of a National Viral Surveillance Organization
    Session Chair: James Lu, Helix
    - Rick Bright, Rockefeller Foundation
  • COVID-19 Testing: Who, When, What? The Challenges of Testing During the Pandemic (PANEL)
    Session Chair: Alan Wu, UCSF
    - Gary Pestano, Biodesix
    - John Barnes, CDC
    - Kathleen Jacobson, CA COVID Testing Task Force
  • Updates in COVID-19 Drug Development
    - Mark Dresser, Gilead Sciences
    - John Fahy, UCSF
    - Yi Shi, University of Pittsburgh
    - Wendy Yeh, Vir Biotechnology
  • Evolving SARS-CoV-2 Vaccines
    Alessandro Sette, La Jolla Institute for Immunology
    - Andrew Allen, Gritstone
  • Accelerating COVID-19 Therapeutic Interventions
    - Stacey Adam, FNIH
  • Past, Present, and Future: How will We Manage the Next Pandemic? (PANEL)
    Session Chair: Julianne McCall, California Initiative to Advance Precision Medicine
    - Lawrence Corey, Fred Hutchinson Cancer Research Center
    - Yvonne A Maldonado, Stanford
    - Robert Wachter, UCSF
    - Tomás Aragón, CDPH